Lexaria Bioscience (LEXX) Assets (2011 - 2026)
Lexaria Bioscience (LEXX) posted Assets of $4.8 million for Q2 2026, down 26.3% sequentially from $6.5 million in Q1 2026, and down 29.07% YoY from $6.7 million in Q2 2025.
Lexaria Bioscience (LEXX) Assets (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Assets for 16 years, with the latest figure at $4.8 million in Q2 2026.
- Quarterly Assets fell 29.07% year-over-year to $4.8 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.8 million (down 29.07% YoY) and the FY2025 annual result came in at $4.2 million, down 52.92% from the prior year.
- Assets retreated to $4.8 million in Q2 2026 per LEXX's latest filing, from $6.5 million in the prior quarter.
- Over five years, Assets peaked at $11.4 million in Q1 2022 and troughed at $114546.0 in Q1 2023.
- A 5-year average of $5.2 million and a median of $5.9 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets soared 8214.68% in 2022, then sank 99.0% in 2023.
- Over 5 years, Assets stood at $118096.0 in 2022, then climbed by 12.3% to $132627.0 in 2023, then jumped by 7284.45% to $9.8 million in 2024, then plunged by 38.22% to $6.1 million in 2025, then dropped by 20.98% to $4.8 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $4.8 million, $6.5 million, and $6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 19.82 Bn |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | 4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 4.78 Mn |
| Feb 28, 2026 | 6.49 Mn |
| Nov 30, 2025 | 6.05 Mn |
| Aug 31, 2025 | 4.18 Mn |
| May 31, 2025 | 6.74 Mn |
| Feb 28, 2025 | 8.68 Mn |
| Nov 30, 2024 | 9.79 Mn |
| Aug 31, 2024 | 8.87 Mn |
| May 31, 2024 | 124,968.00 |
| Feb 29, 2024 | 5.70 Mn |
| Nov 30, 2023 | 132,627.00 |
| Aug 31, 2023 | 3.08 Mn |
| May 31, 2023 | 538,571.00 |
| Feb 28, 2023 | 114,546.00 |
| Nov 30, 2022 | 118,096.00 |
| Aug 31, 2022 | 7.83 Mn |
| May 31, 2022 | 9.14 Mn |
| Feb 28, 2022 | 11.41 Mn |
| Nov 30, 2021 | 11.75 Mn |
| Aug 31, 2021 | 13.27 Mn |